Immunic, Inc. (IMUX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 07, 2025

$1.12

P/E Ratio

N/A

Market Cap

$98.19M

Jan 22, 2024Feb 26, 2024Apr 1, 2024May 2, 2024Jun 5, 2024Jul 9, 2024Aug 8, 2024Sep 12, 2024Oct 17, 2024Nov 21, 2024Jan 7, 2025$0.00$10.00
  • IMUX
Description

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company is headquartered in New York, NY.

Metrics

Overview

  • HQNew York, NY
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerIMUX
  • Price$1.12+2.75%

Trading Information

  • Market cap$98.19M
  • Float96.98%
  • Average Daily Volume (1m)891,898
  • Average Daily Volume (3m)999,928
  • EPS-$1.24

Company

  • RevenueN/A
  • Rev growth (1yr)N/A
  • Net income-$24.37M
  • Gross marginN/A
  • EBITDA marginN/A
  • EBITDA-$25.68M
  • EV$108.93M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B2.38
Documents